Tag: DDD
Aurora Spine receives IRB approval to commence multicentre study for DEXA-C...
Aurora Spine has announced that it has received Institutional Review Board (IRB) approval for its new multicentre study of its DEXA-C cervical interbody system,...
DiscGenics receives FDA RMAT designation for IDCT for degenerative disc disease
DiscGenics has announced that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to Injectable Disc Cell Therapy...
Spinal Stabilization Technologies announces start of LOPAIN2 clinical trial for lumbar...
Spinal Stabilization Technologies has announced the start of the LOPAIN2 clinical trial of its PerQdisc nucleus replacement device in patients with degenerative disc disease...
ROTAIO cervical disc prosthesis a safe and effective treatment option for...
The ROTAIO cervical disc prosthesis (Signus) is a safe and efficient treatment option for those with symptomatic degenerative disc disease and demonstrates highly significant...
Spine BioPharma announces first patient treated in US Phase 3 clinical...
Spine BioPharma recently announced the first patient treated in a Phase 3 clinical study of SB-01. This, according to the company, is the first...
Tritanium posterior lumbar cage an ‘effective alternative’ to PEEK cages for...
For the treatment of degenerative disc disease (DDD), the Tritanium posterior lumbar cage (Stryker) is an effective alternative to polyetheretherketone (PEEK) cages, with higher...
Early study suggests novel, injectable gel may greatly reduce chronic low...
An experimental formulation of a hydrogel, injected into spinal discs, proved safe and effective in substantially relieving chronic low back pain caused by degenerative...
Spine BioPharma completes US$13m Series B financing round
Spine BioPharma, a biopharmaceutical company that aims to develop non-opiate, non-surgical therapies for the treatment of pain and disability from chronic low back pain...
DiscGenics reveals positive interim data of cell therapy for degenerative disc...
DiscGenics has announced positive interim data from its ongoing phase 1/2 clinical trial of IDCT (rebonuputemcel), an allogeneic injectable discogenic cell therapy for degenerative...
Companion Spine raises US$55 million to further develop and market its...
Companion Spine has raised US$55 million in a Series A financing round, with the money going towards the development and commercialisation of its range...
Precision Spine launches the Dakota ACDF standalone system
Precision Spine has announced the launch of the Dakota ACDF standalone system for the treatment of degenerative disc disease (DDD).
The Dakota ACDF system features...
Spinal Stabilization Technologies receives CE Mark and FDA breakthrough designation for...
Spinal Stabilization Technologies (SST) has announced that it has earned the CE Mark and the FDA's breakthrough designation for its PerQdisc™ Nucleus Replacement System...
Cerapedics granted breakthrough device designation for P-15L bone graft
Cerapedics has announced that it has been granted breakthrough device designation by the US Food and Drug Administration (FDA) for its investigational P-15L bone...